Key Insights

Highlights

Success Rate

98% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

1.8%

1 terminated out of 57 trials

Success Rate

97.6%

+11.1% vs benchmark

Late-Stage Pipeline

26%

15 trials in Phase 3/4

Results Transparency

12%

5 of 41 completed with results

Key Signals

5 with results98% success

Data Visualizations

Phase Distribution

38Total
Not Applicable (7)
P 1 (6)
P 2 (10)
P 3 (8)
P 4 (7)

Trial Status

Completed41
Unknown9
Active Not Recruiting2
Recruiting2
Enrolling By Invitation1
Not Yet Recruiting1

Trial Success Rate

97.6%

Benchmark: 86.5%

Based on 41 completed trials

Clinical Trials (57)

Showing 20 of 20 trials
NCT04024163Phase 3Active Not RecruitingPrimary

Prospective Study of Benznidazole for Chagas' Disease Children With Chronic Indeterminate Chagas Disease

NCT05477953Not Yet RecruitingPrimary

An Observational Pregnancy Safety Study in Women Who Were Exposed to the Drug Nifurtimox During Pregnancy to Learn About the Risk of Pregnancy Complications and About the Mother's and Baby's Health

NCT03672487Phase 3CompletedPrimary

Short-course Benznidazole Treatment to Reduce Trypanosoma Cruzi Parasitic Load in Women of Reproductive Age

NCT06632600Phase 2RecruitingPrimary

A Study of Efficacy, Safety, Tolerability of LXE408 in Participants With Chronic Chagas Disease.

NCT04023227Phase 4CompletedPrimary

Efficacy and Safety of Sacubitril/Valsartan Compared With Enalapril on Morbidity, Mortality, and NT-proBNP Change in Patients With CCC

NCT07033325Enrolling By InvitationPrimary

University-Based Chagas Testing in Salta Province, Argentina

NCT05868005Not ApplicableCompleted

Delivering a Multi-disease Screening Tool to Migrant Populations

NCT02625974Phase 3CompletedPrimary

A Study to Learn How Well Nifurtimox Works and How Safe it is in Children Aged 0 to 17 Years With Chagas' Disease, an Inflammatory, Infectious Disease Caused by the Parasite Trypanosoma Cruzi

NCT03981523Phase 2Completed

New Therapies and Biomarkers for Chagas Infection

NCT04984265Phase 1Active Not Recruiting

SBRT in Chagas Disease Ventricular Tachycardia

NCT03191162Phase 2CompletedPrimary

Evaluation of Different Benznidazole Regimens for the Treatment of Chronic Chagas Disease.

NCT04897516Phase 3RecruitingPrimary

Shorter Benznidazole Regimens Compared to the Standard Regimen for Chagas Disease

NCT04274101UnknownPrimary

Nifurtimox Versus Benznidazole Effectiveness and Tolerance for Chagas Disease Treatment

NCT04084379UnknownPrimary

Implementation Strategy of Bio-molecular Techniques for Early Diagnose of Congenital Syphilis and Chagas Diseases

NCT03784391CompletedPrimary

Study on Benefits of Therapy With Nifurtimox in Chagas Disease, a Parasitic Illness Mostly Transmitted to Humans by a Bug, Using Information From Patient Medical Records in Argentina

NCT02327052CompletedPrimary

Assessment of Speckle Tracking Strain Predictive Value for Myocardial Fibrosis in Chagas Disease

NCT03334838Phase 1CompletedPrimary

Study to Assess the Food Effect on the Pharmacokinetics of Nifurtimox Tablets in Chronic Chagas' Patients - Dietary Habits Study

NCT04090489CompletedPrimary

Congenital Chagas Disease: Long Term Follow up of Treated Children. Preliminary Report or Cardiological Evaluation in Chagas Disease Treated Children

NCT00123916Phase 3CompletedPrimary

BENEFIT: Evaluation of the Use of Antiparasital Drug (Benznidazole) in the Treatment of Chronic Chagas' Disease

NCT03350295Phase 1CompletedPrimary

Study Will Evaluate the Relative Bioavailability, Safety, and Tolerability of Single Doses of Nifurtimox 30 mg Tablets Exhibiting Different in Vitro Dissolution Characteristics, and to Evaluate the Relative Bioavailability of Nifurtimox 30 mg and 120 mg

Scroll to load more

Research Network

Activity Timeline